• VyncaCare

  Participated · Equity · Jan 2022

  Vynca provides technology and interdisciplinary care teams to support people living with serious illnesses and to improve experiences for patients and caregivers before and during end‑of‑life transitions. The company partners with healthcare providers, payers and risk‑bearing entities to serve populations including those with congestive heart failure, cancer and end‑stage renal disease. Vynca’s solutions aim to enable clinicians and partners to achieve better outcomes while allowing organizations to enter value‑based care arrangements. The firm highlights the scale of need—more than $205B is spent annually in the U.S. during end‑of‑life transitions—and seeks to expand access nationally. With new capital, Vynca plans to grow its clinical services organization and expand its technology suite to meet the needs of value‑based care programs as well as traditional care paradigms. Vynca provides an end-to-end advance care planning solution that helps health care organizations implement and scale advance care planning. Its technology supports education and engagement in advance care planning conversations, shared decision making, digital completion of documents, and ensures universal document accessibility across the care continuum. The company partners with over 80 hospitals, as well as health plans, ACOs, and five state registries. Led by co-founder and CEO Ryan Van Wert, M.D., Vynca plans to use new funding to expand into new geographies and develop new products. The company recently secured $10.3M in Series B financing to support that expansion and product development. The funding and partnerships aim to increase adoption and accessibility of advance care planning across provider networks.

• Clarapath

  Participated · Series B · Nov 2021

  Clarapath develops robotics, machine vision and digital automation tools to modernize how pathology laboratories process tissue, with its SectionStar system positioned as an all‑in‑one tissue sectioning and transfer solution. SectionStar is described as the first (pending U.S. launch) system that increases capacity, reliability and consistency while reducing the need for highly skilled labor. The company says its automation captures and aggregates new data to improve downstream digital pathology and diagnostic review. Clarapath cites a strained laboratory environment driven by severe labor shortages, rising caseloads and antiquated manual workflows as rationale for its products; the article notes more than 12 million human and veterinary biopsies are performed annually in the U.S. The company operates medical device development in Hawthorne, NY and runs a CLIA‑certified laboratory serving clinical and non‑clinical organizations. With this financing, Clarapath plans to accelerate commercialization of SectionStar and expand sales, service, precision manufacturing and R&D to build an end‑to‑end 'lab of the future.' Clarapath develops SectionStar, a fully automated, all‑in‑one tissue sectioning and transfer system that standardizes and accelerates the preparation of glass slides for pathology. SectionStar consolidates manual cutting, quality control, and decision steps to produce more consistent tissue sections and support AI‑driven analysis. The company says the system increases throughput, reduces reliance on skilled labor, and generates richer datasets for molecular mapping and precision‑medicine research. Clarapath works with research and clinical customers today, including Northwell Health and The Ellison Institute, and operates a CLIA‑certified clinical research organization that offers whole slide imaging and automated image processing. The company plans to launch SectionStar first in the non‑clinical market in the near term while targeting the larger clinical market as its ultimate goal. Recent financing will support product development, team growth, and expanded sales and service efforts.

• Gauss

  Led · Series C · Oct 2020

  Gauss develops computer-vision software for healthcare with a flagship product, Triton, that detects surgical and obstetric hemorrhage in real time and notifies clinicians for timely intervention. Triton received De Novo clearance from the U.S. FDA in 2014 and several follow-on 510(k) clearances, is available on the iPhone, and has been widely adopted by U.S. health systems. The company is advancing a COVID-19 at-home rapid antigen test integrated with a computer-vision app and has an exclusive partnership with Cellex to launch the test. Gauss expects to announce clinical trial results for the at-home test soon and its technology is already powering large-scale, at-home research studies on COVID-19. The company is led by CEO Siddarth Satish and was founded in 2011 in Menlo Park, CA. Gauss will use new funding to continue development and deployment of its at-home COVID-19 testing and computer-vision applications.

No current team members are available.